---
title: "Sinopep-Allsino Biopharmaceutical Passes GMP Inspections for APIs in South Korea, China"
date: "2025-02-11 16:01:10"
summary: "Jiangsu Sinopep-Allsino Biopharmaceutical received good manufacturing practice compliance certifications from South Korea and China's Jiangsu province. These are semaglutide and fulvestrant active pharmaceutical ingredients (API) for export to South Korea as well as epalrestat and sodium picosulfate APIs for domestic production, according to a Tuesday filing with the Shanghai bourse...."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Jiangsu Sinopep-Allsino Biopharmaceutical received good manufacturing practice compliance certifications from South Korea and China's Jiangsu province.

These are semaglutide and fulvestrant active pharmaceutical ingredients (API) for export to South Korea as well as epalrestat and sodium picosulfate APIs for domestic production, according to a Tuesday filing with the Shanghai bourse.

Shares of the biopharmaceutical company were down 3% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250211:G2466180:0/)
